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Background
The soluble nitric oxide (NO)-stimulated guanylyl
cyclase (sGC) uses GTP as a substrate to synthesize the
secondary messenger cGMP [1]. However, sGC is not so
stringent in terms of substrate-specificity and can also
use ATP to produce yet another secondary messenger,
cAMP [1]. Both cAMP and cGMP induce vasodilation.
Recently, it has been proposed that under conditions of
hypoxia, sGC predominantly produces cIMP to induce
vasoconstriction [2]. Chemically, cGMP and cIMP are
very closely related to each other, i.e. the only chemical
difference between the two cyclic nucleotides is the
missing amino group at the 2’-position of the purine
ring (Fig. 1). How can such a small chemical difference
between two molecules lead to opposite biological
effects? To answer this question, we studied cIMP
synthesis, effector activation, inactivation and biological
occurrence.
Methods
We determined cGMP and cIMP concentrations with a
highly sensitive and specific HPLC-MS/MS method that
was previously described in detail [1,3]. We analysed
purified sGCa1b1 [1], recombinant particulate GC-A
(pGC-A) expressed in HEK293 cell membranes or intact
HEK293 cells [3], recombinant cAMP- and cGMP-
dependent protein kinases (PKA and PKG, respectively)
[4], and various recombinant phosphodiesterases (PDEs)
[5,6]. We also determined cIMP concentrations in var-
ious biological systems [7].
Results
Purified sGC and recombinant pGC-A expressed in
HEK293 cells were very effective at producing cIMP. Km
and Vmax values depended on the presence of Mg
2+ or
Mn2+ as divalent cation. Under certain conditions, ITP
clearly surpassed GTP in terms of Vmax. The bacterial
toxins CyaA from Bordetella pertussis and edema factor
from Bacillus anthracis also produced cIMP, but effi-
ciency was very low. However, in intact cells we did not
obtain any evidence for cIMP production by sGC, pGC-
A or bacterial toxins, including ExoY from Pseudomonas
aeruginosa. Cyclic nucleotides activated PKA isoforms
RI and RII in the potency order cAMP > cIMP >
cGMP, and PKGI was activated in the potency order
cGMP > cIMP ~ cAMP. At PKA, all cyclic nucleotides
were full activators, whereas at PKGI , the order of effi-
cacy was cGMP > cIMP > cAMP. With the exception of
PDEs 4B and 8A, all other PDEs studied (PDE1A3, 1B,
2A, 3A, 3B, 5A, 6AB, 7A1, 9A and 11A1), hydrolysed
cIMP very effectively. In 23 cultured mammalian cell
lines from mesenchymal, epithelial and neuronal origin
(6 different species), various primary human and
rat cells, mouse heart and model organisms including
Caenorhabditis elegans, Drosophila melanogaster, Sac-
charomyces cerevisiae, Escherichia coli and Arabidopsis
thaliana we did not identify cIMP. In contrast, all sys-
tems studied contained cAMP, and several systems addi-
tionally contained cGMP.
Conclusions
sGC and pGC-A synthesize cIMP in vitro. However, in
intact cells, there is no evidence for the occurrence of
cIMP and sGC- and pGC-A-mediated cIMP formation.
To this end, we have not yet explicitly studied hypoxic
conditions. cIMP is a low-potency activator of PKA and
PKG. For most PDEs, cIMP is an excellent substrate.
This could result in rapid elimination of endogenous
cIMP in cells. Our attempts to identify cIMP in organs
have been unsuccessful so far. Collectively, presently, we
do not have sufficient experimental evidence to support
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the notion that cIMP serves as second messenger with
functions opposite to those of cAMP and cGMP. Exten-
sive studies with biological models under hypoxic condi-
tions are required. In addition, specific cIMP-binding
proteins have to be identified. It cannot be excluded
that under very specific experimental conditions, cIMP
does have a signalling role. One should also keep in
mind that cyclic nucleotides can exert biological effects
extracellularly via receptors and ion channels.
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Figure 1 Chemical structures of cAMP, cGMP and cIMP
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